EVALUATION OF SURGICAL FACTORS AFFECTING VITREOUS HEMORRHAGE FOLLOWING PORT DELIVERY SYSTEM WITH RANIBIZUMAB IMPLANT INSERTION IN A MINIPIG MODEL

Retina. 2020 Aug;40(8):1520-1528. doi: 10.1097/IAE.0000000000002614.

ABSTRACT

PURPOSE: To develop an animal model of vitreous hemorrhage (VH) to explore the impact of surgical parameters on VH associated with insertion of the Port Delivery System with ranibizumab (PDS) implant.

METHODS: Ninety eyes from 45 treatment-naive male Yucatan minipigs received PDS implant insertion or a sham procedure. The effect of prophylactic pars plana hemostasis, scleral incision length, scleral cauterization, surgical blade type/size, and viscoelastic usage on postsurgical VH was investigated.

RESULTS: Postsurgical VH was detected in 60.0% (54/90) of implanted eyes. A systematic effect on VH was only detected for pars plana hemostasis before the pars plana incision. The percentage of eyes with VH was 96.6% (28/29) among eyes that did not receive prophylactic pars plana hemostasis and 42.4% (24/58) among eyes that did. There was no VH in eyes that received laser ablation of the pars plana using overlapping 1,000-ms spots; pars plana cautery or diathermy was less effective. The majority of all VH cases (83.3% [45/54]) were of mild to moderate severity (involving ≤25% of the fundus).

CONCLUSION: In this minipig surgical model of VH, scleral dissection followed by pars plana laser ablation before pars plana incision most effectively mitigated VH secondary to PDS implant insertion.

PMID:31436674 | PMC:PMC7392584 | DOI:10.1097/IAE.0000000000002614

Description

CONCLUSION: In this minipig surgical model of VH, scleral dissection followed by pars plana laser ablation before pars plana incision most effectively mitigated VH secondary to PDS implant insertion.

pubmed:31436674
https://pubmed.ncbi.nlm.nih.gov/31436674/?utm_source=curl&utm_medium=rss&utm_campaign=None&utm_content=1D1U_2QMDWYKn_cXR-rtstRmreLn3QCrs1Teh4Y_EhqdhU3Q7j&fc=None&ff=20240712054154&v=2.18.0.post9+e462414
Published Date
2019-08-23
Associated Team Member
Retina
Feed Publication Page
40(8):1520-1528
2019
08
Vladimir Bantseev, Chris Schuetz, Helen S Booler, Joshua Horvath, Kristof Hovaten, Signe Erickson, Ellison Bentley, T Michael Nork, William R Freeman, Jay M Stewart, Giulio Barteselli
Approved Therapy
Investigation Type
Development Phase